@misc{10498/39523,
year = {2021},
month = {1},
url = {http://hdl.handle.net/10498/39523},
abstract = {This study provides a comparative survival analysis among most treatments available for moderate-to-severe AD. Regarding systemic drug survival, our findings are in reasonable
agreement with previous studies. Considering survival analysis as a reflection of the performance of a drug in daily practice, the results for dupilumab in our study demonstrate a clear superiority in terms of persistence compared with systemic
therapy. The dropout rate for the dupilumab group was only 6% in 20 months, whereas it was above 65% for all the other drugs under study. A limitation of this study is
the retrospective design, which is dependent on the quality of the medical records.},
publisher = {Oxford University Press},
keywords = {atopic dermatitis},
title = {Drug survival of systemic and biological treatments for moderate-to-severe atopic dermatitis in adults: a multicentre retrospective observational study},
doi = {10.1111/BJD.19428},
author = {Pereyra-Rodríguez, José Juan and Dominguez-Cruz, Javier and Ruiz-Villaverde, Ricardo and Silvestre-Salvador, Juan Fancisco and Galán Gutiérrez, Manuel and Curto-Barredo, Laia and Figueras-Nart, Ignasi and Serra-Baldrich, Esther and Armario Hita, José Carlos},
}